期刊文献+

可溶性PD-1酶联检测试剂盒的研制及其应用 被引量:2

Preparation of sPD-1 ELISA kit and its application
下载PDF
导出
摘要 目的:建立人的可溶性PD-1(sPD-1)酶标检测试剂盒并探讨其检测的临床意义。方法:在已成功获得两株识别位点不同的鼠抗人PD-1分子单克隆抗体(1F2和5F10)的基础上,采用该室制备的鼠抗人PD-1分子单克隆抗体(1F2)作为包被抗体,应用本室制备的单抗5F10经生物素(biotin)标记后作为检测抗体,建立双单抗夹心的人sPD-1酶标检测方法,并对健康供血员、甲亢、血液病患者的血清中sPD-1的含量进行了检测。结果:成功研制了人sPD-1酶联检测试剂盒,其灵敏度为200.00pg/ml。该试剂盒4℃放置1个月,离散度(CV%)<±5.17,回收率为95%~115%,提示该检测试剂盒具有良好的灵敏度、稳定性和准确性。用该试剂盒测得血清中sPD-1的正常值为1.103±0.240ng/ml,再生障碍性贫血患者血清中sPD-1的含量明显高于正常对照组,而甲亢和器官移植病人血清中sPD-1的含量和正常值相比没有显著差异(P<0.05)。结论:成功研制了检测人sPD-1酶标检测试剂盒,并首次发现再生障碍性贫血患者血清中sPD-1的含量较高,该试剂盒在临床病人sPD-1的检测中具有潜在的应有价值。 Objective: To establish the sPD-1 ELISA kit and to detect the amounts of sPD-1 in different diseases. Methods: Two mAbs of mouse anfi-htrman PD-1 ( 1F2 and 5F10) established by our lab were used.The 1F2 mAb was used as coating antibody and the 5F10 which recognized a different epitope was selected to be labeled by biotin. The levels of sPD-1 from serum in normal volunteers and haematology,hyperthyroidism and transplantation patients were detected by the ELISA kit. Results: sPD-1 ELISA kit was established successhtUy with the measuring threshold of 200.00 pg/ml. The sensitivity did not dechne after the kit was stored at 4 ℃ for 1 month. The level of sPD-1 in normal volunteers was 1.103± 0.204 ng/ml. The levels of sPD-1 in aplastic anemia (AA) patients were showed highly increasing compared with those of normal control. The levels of sPD-1 in other patients such as hyperthyroidism and transplantation had no obviously increasing compared with normal control. Conelusion:A specific and sensitive ELISA kit to detect hunman sPD-1 is established. The application of the kit has been performed. It is firstly found that the level of sPD-1 in AA patients is higher than in normal control.h is suggested that the ELISA kit has a potential application in detecting chnic patients of sPD-1.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2008年第9期825-827,841,共4页 Chinese Journal of Immunology
基金 国家自然科学基金(30330540) 苏州大学在职获得博士学位人员基金(13132743)
关键词 PD-1单克隆抗体 可溶性PD-1 酶联免疫吸附试剂盒 PD-1 monoclonal antibody Soluble PD-1,Enzyme-hnked immunoabsorbent
  • 相关文献

参考文献1

二级参考文献24

  • 1lwai Y, Terawaki S, lkegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med, 2003, 198(1): 39-50.
  • 2Volkel D, Blankenfeldt W, Schomburg D, Large-scale production purification and refolding of the full-length cellular prion protein from Syrian golden hamster in Escherichia coli using the glutathione S-transferase-fusion system.Eur J Biochem, 1998, 251(1-2): 462-71.
  • 3Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR Activationinduced expression of human programmed death-I gene in T-lymphocytes.Exp Cell Res, 1997, 232:25-28.
  • 4Mazanet MMI Hughes CC. B7-HI is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol, 2002, 169: 3581-3588.
  • 5Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins Met al.PD- 1 : PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol, 2002, 32(3): 634-643.
  • 6Cox GN, Pratt D, Smith D, McDermott M J, van'der Slice RW. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coll. Protein Expr Purif, 1999, 17(1): 26-32.
  • 7Coyle A J, Gutierrez-Ramos JC. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nat Immunol,2001, 2(3): 203-209.
  • 8Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol,2002, 2:116-126.
  • 9Carreno BM, Collins M. The B7 family ofligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu Rev Immunol, 2002, 20:29-53.
  • 10Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression ofPD-l, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J, 1992, 11:3887-3895.

共引文献2

同被引文献21

  • 1涂来慧.重视不同类型胸腺病理变化在重症肌无力治疗中的价值[J].中华神经科杂志,2005,38(2):67-69. 被引量:8
  • 2Milani M,Ostlie N,Wang W,et al.T cells and cytokines in the pathogenesis of acquired myasthenia gravis.Ann N Y Acad Sci,2003,998:284-307.
  • 3Chambers CA.The expanding world of co-stimulation:the two-signal model revisited.Trends Immunol,2001,22:217-223.
  • 4Okazaki T,Honjo T.PD-1 and PD-1 ligands:from discovery to clinical application.Int Immunol,2007,19:813-824.
  • 5Jaretzki A,Barohn RJ,Emstoff RM,et al.Myasthenia gravis:recommendations for clinical research standards. Neurology,2000,55:16-23.
  • 6Nishimura H,Agata Y,Kawasaki A,et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.Int Immunol,1996,8:773-780.
  • 7Nielsen C,Ohm-Laursen L,Barington T,et al.Alternative splice variants of the human PD-1 gene.Cell Immunol,2005,235:109-116.
  • 8Riley JL.PD-1 signaling in primary T cells.Immunol Rev,2009,229:114-125.
  • 9Selenko-Gebauer N, Majdic O,Szekeres A,et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.J Immunol,2003,170:3637-3644.
  • 10Brown JA,Dorfman DM,Ma FR,et al.Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.J Immunol,2003,170:1257-1266.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部